APIs delivered by sticky webs
GlaxoSmithKline (GSK) has granted 42 Technology worldwide pharmaceutical rights to a new precision powder dispensing technology that can quickly print powdered APIs onto edible or inert webs coated with adhesive to create a novel dose form.
GlaxoSmithKline (GSK) has granted 42 Technology worldwide pharmaceutical rights to a new precision powder dispensing technology that can quickly print powdered APIs onto edible or inert webs coated with adhesive to create a novel dose form. The technology 'sticky web' is based on the discovery that the quantity of powder adhering to a piece of sticky tape is directly proportional to the surface area of the tape. It was originally developed by 42 Technology for GSK as a high-speed process for handling pure APIs.
A statement issued by 42 Technology claims the technology offers numerous benefits, including the elimination of check weighing. Online inspection systems can also be used to validate every powdered area and to improve process feedback.
"Under the terms of our initial agreement, 42 Technology was allowed originally by GSK to exploit sticky web technology for a number of major opportunities outside the pharmaceutical arena," Keith Smith, Manager Strategic Technologies at GSK's pharmaceutical department, said in a statement. "The approach offers considerable promise in many areas and we see benefits in widening the scope of the license. GSK will retain the core patents to sticky web and will support 42 Technology during the coming months in finding additional potential development partners."
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
